Skip to content

Released May 9, 2018, before the open

10-Q filed May 9, 2018, 39 days after period end · 0001144204-18-026625

Q1 2018 · 10-Q
Revenue$4.55M+57.6% vs Q1 2017+5.8% vs Q4 2017
Net Income-$7.24MN/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.50N/M vs Q1 2017no prior Q4 2017 on file
Gross Profit$1,629,000+103.4%
Operating Income-$5,151,000N/M
Operating Cash Flow-$9,413,000N/M
Free Cash Flowderived-$9,662,000N/M
Margins · derived
Gross margin35.8%+8.1 pt vs Q1 2017
Operating margin-113.1%+107.2 pt vs Q1 2017
Net margin-159.0%+1888.4 pt vs Q1 2017

What the release said

The release

Same quarter

MetricQ1 2018Q1 2017Q1 2016Q1 2015
Revenue$4.55M$2.89M$679.00K$1.69M
Net Income-$7.24M-$59.15M-$8.60M-$5.97M
EPS Diluted-$0.50-$0.48-$0.09-$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR